10066- MET-7 RISK FACTORS FOR THE EPILEPSY IN PATIENTS WITH BRAIN METASTASES

Abstract In accordance with the progress of cancer treatment, there is a need for long-term control of epilepsy that develops in metastatic brain tumors. In this study, we examined risk factors for the development of epilepsy in metastatic brain tumors. We retrospectively analyzed 200 patients with metastatic brain tumors treated between January 2010 and December 2023 for clinical information such as tumor site, imaging features, genetic mutations, and treatment details. Overall, median age was 67 years, 112 (56%) were male, and the major primary sites were non-small cell lung cancer (55%), breast cancer (12.5%), and small cell lung cancer (11.5%). Epilepsy occurred in 42 patients (21%). In univariate analysis, maximum tumor size, peritumoral edema, intratumoral hemorrhage, surgical treatment, and nonuse of molecularly targeted drugs were significantly associated with the development of epilepsy. Current guidelines do not recommend prophylactic administration of antiepileptic drugs for metastatic brain tumors. However, with the availability of antiepileptic drugs that have fewer side effects and fewer interactions with chemotherapy, prophylactic administration of antiepileptic drugs in high-risk groups for the development of epilepsy may warrant reconsideration.